Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4359 Treatment response and survival in 163 metastatic colorectal neuroendocrine carcinomas: A prospective cohort from the Nordic NEC registry

Introduction: Colorectal neuroendocrine carcinoma (CR-NEC) is a rare and aggressive disease. Most cases are metastatic at diagnosis and palliative chemotherapy is the only systemic treatment option.

Conference:

Presenting Author: Morken S

Authors: Morken S, Langer S, Knigge U, Hjortland G, Sundlöv A,

Keywords: neuroendocrine carcinoma, NEC, colorectal, chemotherapy,

#4329 Multivariate survival analyses of 544 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) given first-line chemotherapy (NORDIC NEC 2)

Introduction: Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and consist of neuroendocrine tumours G3 (NET G3) and neuroendocrine carcinomas (NEC). They differ in clinical and molecular characteristics, response to treatment and prognosis. Limited prospective data are available on prognostic factors for survival in patients given first-line chemotherapy outside of clinical trials.

Conference:

Presenting Author:

Authors: Sorbye H, Hjortland G, Vestermark L, Ladekarl M, Svensson J,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, digestive, high-grade, neuroendocrine tumour grade 3,

#4103 The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation

Introduction: Tumor evolution with acquisition of more aggressive disease characteristics is a hallmark of disseminated cancer. Metastatic pancreatic neuroendocrine tumors (PanNETs) in particular, show frequent progression from a low/intermediate to a high-grade disease.

Conference:

Presenting Author: Crona J

Authors: Backman S, Botling J, Nord H, Ghosal S, Stålberg P,

Keywords: Pancreatic neuroendocrine tumor, Tumor evolution, Alkylating chemotherapy, Treatment resistance,

#3965 Nordic NEC 2: Characteristics and treatment outcome in a prospective cohort of 698 patients with high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)

Introduction: Digestive high-grade (HG) neuroendocrine neoplasms (NEN) are rare with limited data on epidemiology, treatment benefit and survival.

Conference:

Presenting Author:

Authors: Sorbye H, Hjortland G, Vestermark L, Laderkarl M, Svensson J,

Keywords: NEC, NET G3, digestive, chemotherapy, neuroendocrine neoplasms,

#3486 Treatment response and survival according to molecular alterations in 229 patients with high-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN)

Introduction: HG GEP-NEN consist of well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinoma (NEC). The majority have advanced disease, limited treatment options and a poor prognosis.

Conference:

Presenting Author: Elvebakken H

Authors: Elvebakken H, Venizelos A, Perren A, Couvelard A, Lothe I,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade, gastroenteropancreatic, molecular alteration, molecular marker,